Press Releases

Venaxis Announces Acquisition of BiOptix

CASTLE ROCK, Colo., September 13, 2016 /PRNewswire/ — Venaxis®, Inc. (Nasdaq: APPY), announced today that it has acquired BiOptix Diagnostics, Inc., (“BiOptix”) a Boulder, CO-based privately-held company. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance (“ESPR”) technology platform for the detection of molecular interactions. The technology was developed in conjunction with Dr. John ‘Jan’ Hall, Adjoint Professor, JILA (University of Colorado), who shared the Nobel Prize for Physics in 2005.

Details

BiOptix to Sponsor Scientific Briefing at Upcoming Antibody Engineering & Therapeutics Conference

BOULDER, Colo. — December 4, 2015 — BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, is sponsoring a Scientific Briefing at 1:45pm Monday, December 7, at the Antibody Engineering & Therapeutics Conference & Exhibition being held next week at the San Diego Convention Center.

Details

Moscow Institute of Physics and Technology Partners with BiOptix in Development of Novel Chip to Increase SPR Sensitivity

Boulder, Colo. — Nov. 3, 2015 — BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, today announced that the BiOptix SPR biosensor contributed to the design of a novel, highly sensitive new graphene oxide (GO) biosensor chip developed by the Moscow Institute of Physics and Technology (MIPT).

Details

BiOptix Announces Partnership with XTAL BioStructures

Boulder, Colo. — September 22, 2015 — BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, today announced XTAL Bio-Structures Inc.

Details

BiOptix Announces Simulject™ Application

Boulder, Colo. — August 6, 2015 — BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, today announced their Simulject Application, a tool which allows researchers to inject two different concentrations of an analyte simultaneously on a BiOptix 404pi without the need for regeneration.

Details

BiOptix to Release Advances in Protein Engineering Research at AAPS National Biotech Conference

BOULDER, Colo. — June 8, 2015 — BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, today announced the release of a new study on the biophysical analysis of biotherapeutics done in collaboration with Indiana University, the National Defense Science and Engineering Graduate Fellowship and the National Institute of Allergy and Infectious Disease.

Details

BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry

Boulder, Colorado, January 22, 2015 – BiOptix is pleased to announce the appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry. Scott joins the company after previous scientific leadership positions at Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of his nearly 20 year career in therapeutics discovery and development.

Details